estradiol and norethindrone acetate
estradiol and norethindrone acetate is listed in the FDA National Drug Code directory with 3 NDC codes, marketed under brand names including ESTRADIOL AND NORETHINDRONE ACETATE, ABIGALE LO, ABIGALE. Available dosage form: tablet.
Drug details
- Generic Name
- estradiol and norethindrone acetate
- Brand Names
- ESTRADIOL AND NORETHINDRONE ACETATE, ABIGALE LO, ABIGALE
- Application Number
- ANDA210233
- Sponsor
- Naari Pte. Limited
- NDC Codes
- 3
- Dosage Forms
- TABLET
- Routes
- ORAL
- Active Ingredients
- NORETHINDRONE ACETATE, ESTRADIOL
Indications and Usage
1 INDICATIONS AND USAGE Estradiol and norethindrone acetate tablets are an estrogen and progestin combination indicated in a woman with a uterus for: Treatment of Moderate to Severe Vasomotor Symptoms due to Menopause ( 1.1 ) Treatment of Moderate to Severe Symptoms of Vulvar and Vaginal Atrophy due to Menopause ( 1.2 ) Limitations of Use: When prescribing solely for the treatment of moderate to severe symptoms of vulvar and vaginal atrophy due to menopause, first consider the use of topical vaginal products. Prevention of Postmenopausal Osteoporosis ( 1.3 ) Limitations of Use: When prescribing solely for the prevention of postmenopausal osteoporosis, first consider the use of non-estrogen medications. Consider estrogen therapy only for women at significant risk of osteoporosis. Estradiol and norethindrone acetate tablets are indicated for: 1.1 Treatment of Moderate to Severe Vasomotor Symptoms due to Menopause 1.2 Treatment of Moderate to Severe Symptoms of Vulvar and Vaginal Atrophy due to Menopause Limitation of Use When prescribing solely for the treatment of moderate to severe symptoms of vulvar and vaginal atrophy due to menopause, first consider the use of topical vaginal products. 1.3 Prevention of Postmenopausal Osteoporosis Limitation of Use When prescribing solely for the prevention of postmenopausal osteoporosis, first consider the use of non-estrogen medications. Consider estrogen therapy only for women at significant risk of osteoporosis.